Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Table of Contents                
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Schecter, A. D.
space
  arrow  Fuster, V.
space
 arrow  PubMed                        
space

REPLY

Prinzmetal Angina and Cyproheptadine

right arrow Alison D. Schecter; James H. Chesebro; and Valentin Fuster

15 January 1995 | Volume 122 Issue 2 | Page 155


IN RESPONSE:

Dr. Ambrus emphasizes that inhibition of platelet aggregation is a potential important pathophysiologic mechanism for serotonergic-receptor blockade in vasospasm. Serotonin is initially released when platelets aggregate and initiate a positive feedback loop by releasing adenosine diphosphate, thromboxane A2, and more serotonin.

An early study [1] failed to show a decrease in the number of ischemic episodes in patients with vasospastic angina who were treated with ketanserin, a selective serotonin-receptor (S2) antagonist. Ketanserin was given at concentrations that inhibited in vitro platelet aggregation. The presence of serotonin-receptor families, individual patient characteristics for platelet aggregation, and differing in vivo responses may make the use of other serotonin-receptor antagonists, such as cyproheptadine, clinically efficacious in selected patients.


REFERENCE
space
up arrowTop
dotREFERENCE

1. DeCaterina R, Carpeggiani C, L'Abbate A. A double-blind, placebo-controlled study of ketanserin in patients with Prinzmetal's angina. Circulation. 1984; 69:889-94.

About Letters
space

The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:

•Include no more than 300 words of text, three authors, and five references

•Type with double-spacing

•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.

Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.

Annals welcomes electronically submitted letters.





box Article
 arrow  Table of Contents                
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Schecter, A. D.
space
  arrow  Fuster, V.
space
 arrow  PubMed                        
space


 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online